The rare disease community is experiencing a renaissance of therapeutic innovation, with lysosomal storage disorders leading the charge toward curative treatments. Among these conditions, Mucopolysaccharidosis Type I (MPS I) has emerged as a flagship example of how cutting-edge science can transform previously intractable genetic disorders. With multiple revolutionary therapies advancing through clinical trials, the treatment Read.